MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。
Suramin sodium salt
CAS No. : 129-46-4
MCE 国际站：Suramin sodium salt
产品活性：Suramin sodium salt (Suramin hexasodium salt) 是一种可逆的竞争性蛋白酪氨酸磷酸酶 (PTPases) 抑制剂。Suramin sodium salt 是有效的 sirtuins 抑制剂：SirT1 (IC50=297 nM)，SirT2 (IC50=1.15 μM)，SirT5 (IC50=22 μM)。Suramin sodium salt 是竞争性逆转录酶抑制剂 (DNA topoisomerase II: IC50=5 μM)。Suramin sodium salt 是一种有效的 SARS-CoV-2 RNA 依赖性 RNA 聚合酶 (RdRp) 抑制剂。Suramin sodium salt 有效抑制 IP5K，并且是抗寄生虫 (antiparasitic)，抗肿瘤和抗血管生成剂。
研究领域：Metabolic Enzyme/Protease | Epigenetics | Cell Cycle/DNA Damage | Anti-infection | Apoptosis
作用靶点：Phosphatase | Sirtuin | Reverse Transcriptase | Topoisomerase | SARS-CoV | Parasite | Apoptosis
In Vitro: Suramin sodium salt (Suramin hexasodium salt; 50-600 μg/mL; for 24-96 hours) inhibits cells proliferation in a dose-dependent and time-dependent manner and decreases viability in cancer cells.
Suramin sodium salt (300 μg/mL; for 48 hours) induces cells apoptosis and down-regulates mRNA expression in HeLa cells.
Suramin sodium salt (1 mg/mL; 1 hour) significantly suppresses the phosphorylated ERK1/2.
The IC50 values of HO-8910 PM and HeLa are 319 μg/mL, 476 μg/mL, respectively.
Suramin blocks viral replication in Vero E6 cells.
In Vivo: Suramin sodium salt (Suramin hexasodium salt; 10 mg/kg; IV; twice weekly for 3 weeks) reverses established pulmonary hypertension (PH), thereby normalizing the pulmonary artery pressure values and vessel structure.
相关产品：Covalent Screening Library Plus | Drug Repurposing Compound Library Plus | FDA-Approved Drug Library Plus | FDA-Approved Drug Library Mini | Bioactive Compound Library Plus | Anti-Infection Compound Library | Apoptosis Compound Library | Cell Cycle/DNA Damage Compound Library | Epigenetics Compound Library | Metabolism/Protease Compound Library | FDA-Approved Drug Library | Histone Modification Research Compound Library | Anti-Cancer Compound Library | Antiviral Compound Library | Anti-Aging Compound Library | Drug Repurposing Compound Library | Covalent Screening Library | Antioxidant Compound Library | Reprogramming Compound Library | Oxygen Sensing Compound Library | Anti-Cardiovascular Disease Compound Library | Glutamine Metabolism Compound Library | FDA Approved & Pharmacopeial Drug Library | Anti-Lung Cancer Compound Library | Phosphatase Inhibitor Library | Antiparasitic Compound library | Targeted Diversity Library | Rare Diseases Drug Library | Children’s Drug Library | FDA-Approved Anticancer Drug Library | Human Metabolite Library | Anti-Prostate Cancer Compound Library | Off-patent Drug Library | Metabolic Enzyme Compound Library | Cell Death Library | Multi-Target Compound Library | Radioprotector Library | Bioactive Compound Library Max | MG-132 | Chloroquine | Doxorubicin hydrochloride | Bafilomycin A1 | Tamoxifen | Y-27632 | Paclitaxel | Dexamethasone | Z-VAD-FMK | LY294002 | 2-Deoxy-D-glucose | Angiotensin II human | Acetylcysteine | Staurosporine | Actinomycin D | Puromycin dihydrochloride | SB-431542 | 5-Fluorouracil | Bortezomib | Oxaliplatin | Deferoxamine mesylate | Sorafenib | Trametinib | Gemcitabine | Temozolomide | Etoposide | Rotenone | Mdivi-1 | Monomethyl auristatin E | Decitabine
热门产品线：重组蛋白 | 药物筛选 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物
Trending products：Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Dye Reagents | PROTAC | Isotope-Labeled Compounds
品牌介绍:
• MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；
• 50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
• 产品种类涵盖各种重组蛋白，多肽，常用试剂盒 ，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；
• 提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；
• 设有专业的实验中心和严格的质控、验证体系；
• 提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
• 产品的生物活性多经各国客户实验验证；
• Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
• 专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
• 与世界各大制药公司及知名科研机构建立了长期的合作。
